ImmunoGen Stock News

Over the past 3 months, 6 analysts have published their opinion on Immunogen (NASDAQ:IMGN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a compa

Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last

Citigroup raised Ardelyx, Inc. (NASDAQ: ARDX) price target from $6 to $7. Citigroup analyst Yigal Nochomovitz maintained a Buy rating on the stock. Ardelyx shares rose 9.4% to $2.7685 on Friday. H

Companies in The News Are: IMGN, TGTX, TSLA, MSFT

The National Comprehensive Cancer Network (NCCN) released new guidelines for ovarian cancer treatment, which include ImmunoGen Inc's (NASDAQ: IMGN) Elahere (mirvetuximab soravtansine-gynx) as a pref

Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.

WALTHAM, Mass.--( BUSINESS WIRE )--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, Pre

Gilead (GILD) announces deals with Arcellx, Inc. and ImmunoGen to strengthen its oncology pipeline.

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. Th

ImmunoGen recently gained the accelerated approval of mirvetuximab (Elahere) for resistant ovarian cancers with high FRA expression. As the first-of-its-kind, Elahere would enjoy strong market demands

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vista Outdoor Inc (NYSE: VSTO) can be "bought here. I would not push it, though." Benzinga's analyst ratings data shows a consensus Buy rating

Tuesday, the FDA granted accelerated approval for ImmunoGen Inc's (NASDAQ: IMGN) Elahere (mirvetuximab soravtansine-gynx) for folate receptor alpha (FRα)-positive, platinum-resistant epithelial o

Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last

Gainers Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday. Tenax Therapeutics, Inc. (NASDAQ: TENX) jumped 45.7% to close at $0.1351 on Tuesday. Exagen Inc.

ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.